Favorable Decision of the Supreme Court on Lawsuit on Patent Right Held in Relation to Otsuka Pharmaceutical Foods Containing Equol
2022-11-20
专利侵权
Otsuka Pharmaceutical Co., Ltd. (Otsuka) hereby announces that Otsuka has obtained a favorable decision in a patent infringement action against Daicel Corporation (hereinafter "Daicel") and Advanced Medical Care Inc. (hereinafter "AMC").
As announced in the news release dated February 10, 2022, entitled 'Favorable Judgment on Lawsuit on Patent Right Held in Relation to Otsuka Pharmaceutical Foods Containing Equol', Otsuka obtained a favorable judgment from the Intellectual Property High Court on February 9, 2022 in a patent infringement lawsuit against Daicel and AMC. In response to this judgment, Daicel and AMC filed a final appeal and a petition for acceptance of final appeal with the Supreme Court, but these have both been dismissed by the Supreme Court.
With respect to Otsuka's patent right for Equol-containing foods (Patent Registration No. 6275313; Title of Invention: Equol-containing extract and method for producing the same, equol extraction method, and food containing equol; hereinafter the "Patent Right"), Otsuka filed a patent infringement action arguing that Daicel's act of manufacturing and selling "Flavocell EQ-5", and AMC's act of manufacturing and selling "Equol + Lactobionic Acid" using "Flavocell EQ-5" as a raw material infringed their patent.
In this case, although the Tokyo District Court, the court of first instance, rendered a judgment dismissing Otsuka's claims on September 17, 2020, the Intellectual Property High Court, the court of second instance, overturned the judgment of the first instance and ruled in favor of Otsuka(*1) on February 9, 2022. The Supreme Court, the court of final appellate instance, dismissed the final appeal and refused to hear the case in its decisions dated November 11, 2022, and the decision of the Intellectual Property High Court, which found that a patent infringement had occurred and granted injunctions against the infringing parties, has thereby become final and binding (*2).
Thus, Daicel is prohibited from manufacturing and selling "Flavocell EQ-5", and AMC is prohibited from manufacturing and selling "Equol + Lactobionic Acid" using "Flavocell EQ-5" as a raw material.
Otsuka has filed multiple patent infringement actions seeking damages on the ground of infringement of the Patent Right by "Flavocell EQ-5" and supplement products using Flavocell EQ-5, which are now pending before the Tokyo District Court.
Otsuka will continue to vigorously defend and protect its inventions in relevant fields of technology, and provide safeand high-quality products and information to support people's health based on scientific evidence.
*1
Court
Intellectual Property High Court
Case number
2020 (Ne) #10059
Case name
Appeal Case Seeking Injunction against Infringement of Patent Right
Appellant (First Instance Plaintiff)
Appellee (First Instance Defendant)
Appellee (First Instance Defendant)
*2
Court
The Supreme Court
Case number
2022 (O) #913
Case name
Final Appeal Case Seeking Injunction against Infringement of Patent Right
Final Appellant (Second Instance Appellee)
Final Appellee (Second Instance Appellant)
Court
The Supreme Court
Case number
2022 (Ju) #1150
Case name
Petition for Acceptance of Final Appeal Seeking Injunction against Infringement of Patent Right
Petitioner (Second Instance Appellee)
Respondent (Second Instance Appellant)
Court
The Supreme Court
Case number
2022 (Ju) #1151
Case name
Petition for Acceptance of Final Appeal Seeking Injunction against Infringement of Patent Right
Petitioner (Second Instance Appellee)
Respondent (Second Instance Appellant)
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
-靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。